Table 1.

Pancreatic ductal carcinoma and cancer subtyping signatures and studies used in this study

	Technique of discovery	Sub‐type	Prognosis	Composition	Therapeutics
Collisson	Non‐negative matrix factorization (NMF) analysis with consensus clustering	Classical	Good	N/A	Erlotinib
		Exocrine	Average	N/A	Non‐proposed
		Quasi‐mesenchymal	Poor	N/A	Gemcitabine
Moffitt	Non‐negative matrix factorization (NMF) and digital separation	Tumour: classical	Average (median survival 19 months)	N/A	N/A
		Tumour: basal‐like	Poor (median survival 11 months)	N/A	Better response to adjuvant therapy
		Stroma: normal	Good (median survival 20 months)	Stellate cells	N/A
		Stroma: activated	Poor (median survival 15 months)	Macrophages	N/A
Bailey	Unsupervised clustering	Squamous	Poor	Macrophages	N/A
		Pancreatic Progenitor	N/A	N/A	N/A
		Immunogenic	N/A	B cells and T cells	Checkpoint blockade
		ADEX	N/A
Sivakumar	Master regulator Analysis	Notch	Good	T cell infiltration	Immunotherapy
		Cell cycle	Average	N/A	Adjuvant therapy
		Hedgehog	Poor	Macrophages	N/A